Management of neonatal cholestasis

Cholestasis is a frequent occurrence in newborns, affecting one in every 2500 infants. Immaturity of hepatic metabolic and excretory functions contributes to decreased bile production and transport. The potential causes of neonatal cholestasis are extensive, but most cases fall into a few categories, including anatomic, metabolic and infectious. Pruritus and malabsorption are common manifestations of neonatal cholestasis, regardless of etiology. Medical management of cholestasis is largely supportive, treating the complications of cholestasis rather than the underlying mechanism. Medications for pruritus have variable efficacy and include ursodeoxycholic acid, cholestyramine and rifampin. Fat-soluble vitamin supplementation is often required secondary to fat malabsorption. Enteral absorption of long-chain triglycerides is also decreased, necessitating formulas high in medium-chain triglycerides. Infants may require 125% of the recommended daily allowance of calories for adequate growth and supplementation...

[1]  N. Bergasa.  Update on the treatment of the pruritus of cholestasis. , 2008, Clinics in liver disease.

[2]  A. Francavilla,et al.  Cholestasis induced by total parenteral nutrition. , 2008, Clinics in liver disease.

[3]  J. Cies,et al.  Treatment of cholestatic pruritus in children. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  A. Francavilla,et al.  Total parenteral nutrition-related gastroenterological complications. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  D. von Allmen,et al.  Relief of intractable pruritus in Alagille syndrome by partial external biliary diversion. , 2006, Journal of pediatric surgery.

[6]  R. Sokol,et al.  Comparison of indices of vitamin A status in children with chronic liver disease , 2005, Hepatology.

[7]  S. Sahlin,et al.  Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. , 2005, Gastroenterology.

[8]  Henry W. Lim,et al.  Ultraviolet phototherapy for pruritus , 2005, Dermatologic therapy.

[9]  K. Morin.  Fat-soluble vitamins E and K. , 2005, MCN. The American journal of maternal child nursing.

[10]  C. Yurdaydın,et al.  Fatigue of cholestasis and the serotoninergic neurotransmitter system in the rat , 2005, Hepatology.

[11]  A. Mancuso,et al.  Pruritus in cholestatic and other liver diseases , 2003 .

[12]  A. Burroughs,et al.  Review article: pruritus in cholestatic and other liver diseases. , 2003, Alimentary pharmacology & therapeutics.

[13]  J. van Limbeek,et al.  Itching after intrathecal morphine. Incidence and treatment. , 2000, European journal of anaesthesiology.

[14]  R. Sokol,et al.  Use of rifampin for severe pruritus in children with chronic cholestasis. , 1999, Journal of pediatric gastroenterology and nutrition.

[15]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.

[16]  K. Kowdley.  Lipids and lipid-activated vitamins in chronic cholestatic diseases. , 1998, Clinics in liver disease.

[17]  C. Hollands,et al.  Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. , 1998, Journal of pediatric surgery.

[18]  R. Sokol,et al.  Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. , 1998, Journal of pediatric gastroenterology and nutrition.

[19]  H. Gollnick,et al.  Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? , 1997, Inflammation Research.

[20]  B. Specker,et al.  The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: a preliminary report. , 1997, Journal of pediatric gastroenterology and nutrition.

[21]  J. Heubi,et al.  Fat‐soluble vitamin deficiency in infants and children , 1993, Current opinion in pediatrics.

[22]  B. Specker,et al.  Bone mineral content in infants and children with chronic cholestatic liver disease. , 1993, Pediatrics.

[23]  B. Hollis,et al.  d-α-Tocopheryl Polyethylene Glycol-1000 Succinate Enhances the Absorption of Vitamin D in Chronic Cholestatic Liver Disease of Infancy and Childhood , 1992, Pediatric Research.

[24]  P. Whitington,et al.  Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. , 1988, Gastroenterology.

[25]  S. Özsoylu,et al.  Hepatic and Serum Levels of Zinc, Copper, and Magnesium in Childhood Cirrhosis , 1986, Journal of pediatric gastroenterology and nutrition.

[26]  M. Korman,et al.  Cholestyramine induced hyperchloremic metabolic acidosis. , 1984, Australian and New Zealand journal of medicine.

[27]  D. Wingate.  Gastrointestinal disease: pathophysiology, diagnosis, management , 1984 .

[28]  J. Summerfield,et al.  Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. , 1982, Clinical science.

[29]  J. Bloomer,et al.  Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. , 1977, Gastroenterology.

[30]  D. Varadi.  Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. , 1974, Archives of dermatology.